Vorasidenib with PET scans for recurrent low-grade glioma
Part of Cancer clinical trials.
This trial tests whether the drug vorasidenib, guided by a special PET scan, can help people with certain low-grade brain tumors that have come back or are still present after surgery. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a grade 2 or 3 glioma that has an IDH mutation (a genetic change found in some brain tumors).
- The tumor has come back after treatment or is still present after surgery.
- You have at least one measurable tumor area that is at least 1 cm by 1 cm on an MRI scan.
- You are able to care for yourself (Karnofsky score of 80 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
This trial tests a new targeted therapy called safusidenib for people whose brain tumor (glioma) has an IDH1 mutation and who have already taken vorasidenib but the tumor kept growing. The study aims to see if safusidenib can help when vorasidenib stops working.
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This study uses a special type of PET/MRI scan to look for a common genetic change (IDH mutation) in brain tumors (gliomas). The goal is to improve how doctors diagnose and treat these tumors.
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.